Dulaglutide + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cardiovascular Disease
Conditions
Cardiovascular Disease, Diabetes Mellitus, Type 2
Trial Timeline
Jul 22, 2011 → Aug 21, 2018
NCT ID
NCT01394952About Dulaglutide + Placebo
Dulaglutide + Placebo is a phase 3 stage product being developed by Eli Lilly for Cardiovascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01394952. Target conditions include Cardiovascular Disease, Diabetes Mellitus, Type 2.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03315780 | Approved | Completed |
| NCT02963766 | Phase 3 | Completed |
| NCT02973100 | Phase 2 | Completed |
| NCT02750410 | Approved | Completed |
| NCT01667900 | Phase 1 | Completed |
| NCT01394952 | Phase 3 | Completed |
Competing Products
20 competing products in Cardiovascular Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| raloxifene + placebo | Eli Lilly | Phase 3 | 77 |
| Evacetrapib | Eli Lilly | Phase 1 | 33 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| Prasugrel (CS-747) + Clopidogrel | Eli Lilly | Phase 2 | 52 |
| Rosuvamibe + Monorova | Yuhan | Approved | 85 |
| Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin | Yuhan | Approved | 85 |
| Rosuvamibe + Monorova | Yuhan | Approved | 85 |
| Prasugrel (Crushed tablets) + Prasugrel (Integral tablets) | Daiichi Sankyo | Approved | 85 |
| Lexiscan | Astellas Pharma | Phase 2 | 52 |
| mirabegron + tamsulosin | Astellas Pharma | Phase 1 | 33 |
| TRC150094 | Torrent Pharmaceuticals | Phase 1/2 | 41 |
| Lorcaserin hydrochloride + Placebo | Eisai | Approved | 85 |
| Lepodisiran Sodium + Placebo | Eli Lilly | Phase 3 | 77 |
| Retatrutide + Placebo | Eli Lilly | Phase 3 | 77 |
| Empagliflozin + Placebos | Eli Lilly | Approved | 85 |
| Evacetrapib + Placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + AZD0780 | AstraZeneca | Phase 2 | 52 |
| Risk of low dose aspirin discontinuation | AstraZeneca | Pre-clinical | 23 |
| Midazolam + AZD5718 | AstraZeneca | Phase 1 | 33 |
| 14C]AZD4831 Oral Solution | AstraZeneca | Phase 1 | 33 |